McKinney Capital Management LLC bought a new position in Zoetis Inc. (NYSE:ZTS – Free Report) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 14,364 shares of the company’s stock, valued at approximately $1,003,000.
Other large investors have also recently added to or reduced their stakes in the company. Cassaday & Co Wealth Management LLC acquired a new stake in shares of Zoetis in the 1st quarter valued at about $28,000. Wellington Grp LLC boosted its position in shares of Zoetis by 6,675.0% during the first quarter. Wellington Grp LLC now owns 271 shares of the company’s stock worth $32,000 after buying an additional 267 shares during the period. University of Texas Texas AM Investment Management Co. acquired a new position in shares of Zoetis during the second quarter worth about $25,000. Dunhill Financial LLC grew its holdings in shares of Zoetis by 519.3% during the second quarter. Dunhill Financial LLC now owns 353 shares of the company’s stock worth $25,000 after buying an additional 296 shares in the last quarter. Finally, Dakota Community Bank & Trust NA grew its holdings in shares of Zoetis by 112.4% during the first quarter. Dakota Community Bank & Trust NA now owns 393 shares of the company’s stock worth $46,000 after buying an additional 208 shares in the last quarter. Institutional investors own 92.80% of the company’s stock.
Zoetis Stock Performance
Shares of ZTS traded up $0.69 during midday trading on Friday, reaching $83.65. The stock had a trading volume of 3,151,935 shares, compared to its average volume of 4,644,448. The firm has a 50 day simple moving average of $76.28 and a 200-day simple moving average of $91.56. Zoetis Inc. has a one year low of $68.77 and a one year high of $132.49. The firm has a market cap of $33.99 billion, a PE ratio of 14.23, a P/E/G ratio of 1.20 and a beta of 0.67. The company has a current ratio of 2.35, a quick ratio of 1.40 and a debt-to-equity ratio of 2.51.
Zoetis (NYSE:ZTS – Get Free Report) last issued its earnings results on Thursday, November 5th. The company reported $1.75 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.51 by $0.24. Zoetis had a net margin of 26.15% and a return on equity of 85.90%. The company had revenue of $2.39 billion for the quarter, compared to analysts’ expectations of $2.30 billion. During the same period in the prior year, the firm earned $1.70 EPS. Zoetis’s quarterly revenue was down 1.3% compared to the same quarter last year. As a group, sell-side analysts anticipate that Zoetis Inc. will post 6.29 EPS for the current year.
Zoetis Dividend Announcement
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 1st. Shareholders of record on Friday, October 30th will be paid a $0.53 dividend. The ex-dividend date is Friday, October 30th. This represents a $2.12 annualized dividend and a yield of 2.5%. Zoetis’s dividend payout ratio is currently 36.05%.
Wall Street Analyst Weigh In
A number of brokerages recently issued reports on ZTS. BTIG Research dropped coverage on Zoetis in a research report on Friday, October 30th. They issued a “buy” rating and a $200.00 target price on the stock. Piper Sandler decreased their price target on shares of Zoetis from $90.00 to $80.00 and set a “neutral” rating for the company in a research note on Monday, August 10th. Weiss Ratings raised shares of Zoetis from a “sell (d)” rating to a “sell (d+)” rating in a research note on Thursday, October 29th. Jefferies Financial Group lifted their price objective on shares of Zoetis from $83.00 to $85.00 in a report on Friday, November 6th. Finally, Zacks Research raised shares of Zoetis from a “strong sell” rating to a “hold” rating in a research report on Monday, October 26th. Eight analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $101.25.
Get Our Latest Research Report on ZTS
About Zoetis
Zoetis is an animal health company that discovers, develops, manufactures and markets medicines, vaccines, diagnostic products and other services for animals. Its products support both companion animals, such as dogs and cats, and livestock, including cattle, pigs, poultry, sheep and fish. The company’s offerings include treatments for pain, infections and skin conditions, as well as vaccines, parasiticides, diagnostic tools and genetic testing services. Zoetis serves veterinarians, livestock producers and other animal health professionals around the world.
See Also
- Five stocks we like better than Zoetis
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS – Free Report).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.
